Uncategorized

Vistagen today announced that it has enrolled the first patient in its PALISADE-3 Phase 3 trial of fasedienol, an investigational pherine candidate in development for the acute treatment of social anxiety disorder (SAD).

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia.

The new company includes 3M’s medical, dental, health IT and filtration products.

The company has developed a virtual reality surgical platform for training and assessment.

AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a land-based aquaculture company utilizing technology to enhance productivity and sustainability, today announced the Company’s financial results for the fourth quarter and full year ended December 31, 2023.

3M completed the planned spin-off of its health care business, which formally launches Solventum Corporation as an independent company.

Aculys Pharma, Inc. announces the appointment of Hidemasa Tanigaki as Chief Executive Officer and Representative Director, effective March 29th.

Foresee Pharmaceuticals, announces the positive safety review by the independent Data and Safety Monitoring Board for its Casppian Phase 3 registration study.

Avery Dennison Corporation will host its first quarter 2024 earnings conference call in a live webcast at 12:00 p.m. ET on Wednesday, April 24, 2024.

Merck, known as MSD outside of the United States and Canada, will hold its first-quarter 2024 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, April 25.